11 October 2016 - PHARMAC is pleased to announce that the approval of an agreement with GlaxoSmithKline for the funding of the HIV treatments, dolutegravir sodium (Tivicay) and abacavir sulphate with lamivudine (Kivexa).

This was the subject of a consultation letter dated 8 September 2016. No changes were made to the proposal following consultation.

In summary, the effect of the decision is that from 1 November 2016:

• Dolutegravir sodium (Tivicay) will be will be fully funded in DHB hospitals and the community, subject to certain clinical criteria being met
• There will be a decrease in the price and subsidy of abacavir sulphate with lamivudine (Kivexa).

Read PHARMAC press release